Nerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset

Terrence West, MBA, joins as New Business, Virtual CEO Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and

Related Keywords

Italy ,Boston ,Massachusetts ,United States ,Nerviano ,Lombardia ,San Francisco ,California ,Italian ,Kostenloser Wertpapierhandel ,Lisa Mahnke ,Head Of Program Management ,Program Management ,Ziopharm Oncology ,Head Of Clinical Development At Bicycle Therapeutics ,Leadership Team ,Merck Kga ,Merck Kgaa ,Nerviano Medical Sciences Inc ,Roche Group ,University Of Phoenix ,University Of Arizona ,Nerviano Medical Sciences ,Terrence West ,New Business ,Board Member ,Chief Medical Officer ,Hugues Dolgos ,Chief Executive Officer ,Executive Leadership Team ,Vice President ,Interim Head ,Clinical Development ,Bicycle Therapeutics ,Executive Director ,West Coast ,Stryker Regenerative Medicine ,Operations Officer ,Medical ,Ciences ,Trengthens ,Executive ,Team ,Maximize ,Cdh1 ,Adh2 ,Inhibitor ,Sset ,